Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
PaperCitations, authors & open-access status
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 65 citations, 2018 year and bronze oa status.
65
Citations
2018
Year
bronze
OA Status